Atara Biotherapeutics, Inc. (ATRA) CEO Isaac E. Ciechanover Sells 4,400 Shares
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,400 shares of the stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $14.65, for a total value of $64,460.00. Following the transaction, the chief executive officer now owns 743,675 shares in the company, valued at $10,894,838.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Shares of Atara Biotherapeutics, Inc. (ATRA) remained flat at $$14.55 on Friday. The company’s stock had a trading volume of 255,203 shares, compared to its average volume of 175,179. Atara Biotherapeutics, Inc. has a 12-month low of $11.80 and a 12-month high of $23.00.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.05). equities analysts expect that Atara Biotherapeutics, Inc. will post -4 EPS for the current year.
Institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in shares of Atara Biotherapeutics in the 3rd quarter worth $142,000. Voya Investment Management LLC lifted its holdings in shares of Atara Biotherapeutics by 16.2% in the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,651 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Atara Biotherapeutics in the 3rd quarter worth $170,000. State of Wisconsin Investment Board bought a new position in shares of Atara Biotherapeutics in the 2nd quarter worth $252,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Atara Biotherapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 1,369 shares in the last quarter. Institutional investors own 85.61% of the company’s stock.
A number of equities analysts have issued reports on ATRA shares. Jefferies Group restated a “buy” rating and set a $30.00 price target on shares of Atara Biotherapeutics in a report on Thursday, October 5th. Canaccord Genuity restated a “buy” rating and set a $47.00 price target on shares of Atara Biotherapeutics in a report on Monday, September 11th. Zacks Investment Research cut Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Goldman Sachs Group restated a “neutral” rating and set a $20.00 price target on shares of Atara Biotherapeutics in a report on Friday, October 6th. Finally, ValuEngine upgraded Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $24.40.
TRADEMARK VIOLATION NOTICE: This piece was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://theolympiareport.com/2017/12/16/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-4400-shares.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.